GSK 2862277

Drug Profile

GSK 2862277

Alternative Names: 2862277; GSK2862277

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antibodies
  • Mechanism of Action Type 1 tumour necrosis factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute lung injury

Most Recent Events

  • 08 Nov 2017 GlaxoSmithKline terminates a phase II trial due to protocol defined stopping criteria not met in Acute lung injury in United Kingdom (Inhalation) (NCT02221037)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Acute-lung-injury(In volunteers) in United Kingdom (IV, Infusion)
  • 01 Apr 2015 Phase-II clinical trials in Acute lung injury in United Kingdom (Inhalation) (NCT02221037)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top